Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Strangvac, a vaccine against equine strangles, available for sale in Denmark
Stockholm, May 31, 2022 – Intervacc announces today that Strangvac®, a vaccine against the highly contagious infectious disease equine strangles, has been released for sale in Denmark. “Strangvac® is now available and in stock at our logistics partner in...Interim report January – March 2022
The period in summary First quarter January 1 – March 31, 2022 On March 23 the first batch of Strangvac was released for sale in Sweden.Intervacc has applied for supplementary protection certificates (SPCs) for Strangvac in key European markets. SPCs are an...Intervacc progresses vaccine to prevent mastitis in dairy cows caused by Staphylococcus aureus
Stockholm, May 19, 2022 – Intervacc AB (publ) announces the initiation of a proof-of-concept study to measure the effectiveness of a vaccine to protect dairy cows against mastitis caused by Staphylococcus aureus following successful safety and immunogenicity...Notice of annual general meeting in Intervacc AB (publ)
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Tuesday 14 June 2022 at 5.00 p.m. at Good Morning Hotel, Västertorpsvägen 131, in Hägersten. The Board of Directors...Positive results in proof-of-concept study to develop a vaccine against Streptococcus suis infection in pigs
Stockholm, April 25, 2022 – Intervacc AB (publ) announces positive results from a proof-of-concept study where piglets from vaccinated sows were protected against experimental challenge with Streptococcus suis. The study showed that piglets from sows that had...Nyhetstjänster
